ABUS Arbutus Biopharma Corp

Price (delayed)

$3.05

Market cap

$293.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$217.47M

Highlights
The company's EPS has surged by 64% YoY and by 4% QoQ
Arbutus Biopharma's equity has surged by 56% YoY and by 12% QoQ
Arbutus Biopharma's net income has soared by 54% YoY but it has decreased by 4% from the previous quarter
ABUS's quick ratio has soared by 52% QoQ but it is down by 7% YoY

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
96.39M
Market cap
$293.98M
Enterprise value
$217.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.55
Price to sales (P/S)
37.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.86
Earnings
Revenue
$7.54M
EBIT
-$62.52M
EBITDA
-$60.6M
Free cash flow
-$54.2M
Per share
EPS
-$0.96
Free cash flow per share
-$0.58
Book value per share
$1.19
Revenue per share
$0.08
TBVPS
$1.57
Balance sheet
Total assets
$146.24M
Total liabilities
$32.09M
Debt
$2.91M
Equity
$114.15M
Working capital
$130.65M
Liquidity
Debt to equity
0.03
Current ratio
20.52
Quick ratio
19.91
Net debt/EBITDA
1.26
Margins
EBITDA margin
-804.2%
Gross margin
100%
Net margin
-879.3%
Operating margin
-794.1%
Efficiency
Return on assets
-61.4%
Return on equity
-83%
Return on invested capital
-113.9%
Return on capital employed
-44.8%
Return on sales
-829.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
10.51%
1 week
10.51%
1 month
3.39%
1 year
-27.03%
YTD
-14.08%
QTD
0.66%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$7.54M
Gross profit
$7.54M
Operating income
-$59.85M
Net income
-$66.27M
Gross margin
100%
Net margin
-879.3%
ABUS's operating margin has surged by 61% year-on-year and by 4.2% since the previous quarter
The net margin has surged by 58% year-on-year and by 4.6% since the previous quarter
The company's operating income has surged by 57% YoY but it fell by 4.4% QoQ
Arbutus Biopharma's net income has soared by 54% YoY but it has decreased by 4% from the previous quarter

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
2.55
P/S
37.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.86
The company's EPS has surged by 64% YoY and by 4% QoQ
Arbutus Biopharma's equity has surged by 56% YoY and by 12% QoQ
ABUS's price to book (P/B) is 54% higher than its 5-year quarterly average of 1.5 but 11% lower than its last 4 quarters average of 2.6
The price to sales (P/S) is 24% lower than the 5-year quarterly average of 45.0
Arbutus Biopharma's revenue has increased by 10% YoY and by 9% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 63% YoY and by 4% QoQ
The ROIC has soared by 61% year-on-year but it has declined by 11% since the previous quarter
Arbutus Biopharma's return on assets has increased by 49% YoY and by 5% QoQ
The ROE is up by 48% year-on-year and by 8% since the previous quarter

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
The company's current ratio has surged by 53% QoQ but it fell by 6% YoY
ABUS's quick ratio has soared by 52% QoQ but it is down by 7% YoY
The debt is 97% smaller than the equity
Arbutus Biopharma's equity has surged by 56% YoY and by 12% QoQ
ABUS's debt to equity is down by 25% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.